NextGen Sciences divests electrophoresis business to Sigma-Aldrich

March 6, 2009

LCGC Europe eNews

LCGC Europe eNews-03-06-2009, Volume 0, Issue 0

NextGen Sciences has sold its electrophoresis business to Sigma-Aldrich in exchange for a cash payment and royalty payments on revenues for three years. The deal involves the acquisition of the automated gel casting unit, the a2DEoptimizer and optigels, the range of large format pre-cast gels.

NextGen Sciences has sold its electrophoresis business to Sigma-Aldrich in exchange for a cash payment and royalty payments on revenues for three years. The deal involves the acquisition of the automated gel casting unit, the a2DEoptimizer and optigels, the range of large format pre-cast gels. Sigma-Aldrich will focus primarily on the supply of optigels, initially to the North American and European markets.

This announcement is the end of a strategic realignment of NextGen Sciences and follows on from the divestiture of the non-core ‘gene to protein’ automation and software business at the end of last year. Dr Michael Pisano, CEO of NextGen Sciences, commented: "The sale completes the disposal of our noncore businesses, enabling us to focus on our biomarkerexpress services. In future, customers for electrophoresis products will benefit from Sigma-Aldrich’s knowledge and reach."

Visit NextGen’s website at www.nextgensciences.com

For more about Sigma-Aldrich visit www.sigma-aldrich.com